Manufacturer of Controlled Substances; Notice of Application, 9592-9593 [E8-3175]
Download as PDF
<![CDATA[
9592
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
Schedule
Drug
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
DEPARTMENT OF JUSTICE
II
Drug Enforcement Administration
II
II
II
II
II
II
II
Importer of Controlled Substances;
Notice of Registration
pwalker on PROD1PC71 with NOTICES
The company plans to import
reference standards for sale to
researchers and analytical labs.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA. 22152; and must
be filed no later than March 24, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3178 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
16:34 Feb 20, 2008
Jkt 214001
By Notice dated November 6, 2007
and published in the Federal Register
on November 16, 2007 (72 FR 64678–
64679), Fisher Clinical Services Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Noroxymorphone (9668),
a basic class of controlled substance
listed in schedule II.
The company plans to import the
listed controlled substance for analytical
research and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Fisher Clinical Services Inc. to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Fisher
Clinical Services Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3171 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Lisdexamfetamine
(1205), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for sale to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537, or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than
April 21, 2008.
Dated: February 13, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3176 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 2, 2008,
Siemens Healthcare Diagnostics Inc.,
100 GBC Drive, Mail Stop 514, Newark,
Delaware 19702, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
Drug
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on December 10, 2007,
Johnson Matthey, Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by letter
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
Schedule
I
II
II
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls which are
DEA exempt products.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
E:\FR\FM\21FEN1.SGM
21FEN1
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537, or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than
April 21, 2008.
Dated: February 13, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3175 Filed 2–20–08; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 10, 2008,
Roche Diagnostics Operations, Inc.,
Attn: Regulatory Compliance, 9115
Hague Road, Indianapolis, Indiana
46250, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedules I and II:
Schedule
pwalker on PROD1PC71 with NOTICES
I
I
I
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
16:34 Feb 20, 2008
Jkt 214001
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
BILLING CODE 4410–09–P
[TA–W–62,422]
Curtain & Drapery Fashions Including
On-Site Leased Workers From Paychex
Business Solutions, Lowell, NC;
Amended Certification Regarding
Eligibility To Apply for Worker
Adjustment Assistance and Alternative
Trade Adjustment Assistance
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
VerDate Aug<31>2005
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3179 Filed 2–20–08; 8:45 am]
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols
(THC)
(7370).
Alphamethadol (9605) ..................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Methadone (9250) ........................
Morphine (9300) ...........................
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3177 Filed 2–20–08; 8:45 am]
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 21, 2008.
9593
By Notice dated September 21, 2007,
and published in the Federal Register
on September 27, 2007, (72 FR 54930),
ISP Freetown Fine Chemicals, 238
South Main Street, Assonet,
Massachusetts 02702, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
Drug
Schedule
2,5–Dimethoxyamphetamine
(7396).
Amphetamine (1100) ....................
Phenylacetone (8501) ..................
I
II
II
The company plans to manufacture
Phenylacetone to be used in the
manufacture of Amphetamine for
distribution to its customers. The bulk
2,5–Dimethoxyamphetamine will be
used for conversion into non-controlled
substances.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of ISP
Freetown Fine Chemicals to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated ISP Freetown Fine
Chemicals to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
In accordance with section 223 of the
Trade Act of 1974 (19 U.S.C. 2273), and
section 246 of the Trade Act of 1974 (26
U.S.C. 2813), as amended, the
Department of Labor issued a
Certification of Eligibility to Apply for
Worker Adjustment Assistance and
Alternative Trade Adjustment
Assistance on December 19, 2007,
applicable to workers of Curtain &
Drapery Fashions, Lowell, North
Carolina. The notice was published in
the Federal Register on January 16,
2008 (72 FR 2943).
At the request of the State agency, the
Department reviewed the certification
for workers of the subject firm. The
workers were engaged in the production
of curtains, bedspreads and comforters.
New information shows that leased
workers of Paychex Business Solutions
were employed on-site at the Lowell,
North Carolina location of Curtain &
Drapery Fashions. The Department has
determined that these workers were
sufficiently under the control of Curtain
& Drapery Fashions to be considered
leased workers.
Based on these findings, the
Department is amending this
certification to include leased workers
of Paychex Business Solutions working
on-site at the Lowell, North Carolina
location of the subject firm.
The intent of the Department’s
certification is to include all workers
employed at Curtain & Drapery
Fashions, Lowell, North Carolina who
were adversely impacted by increased
customer imports of curtains,
bedspreads and comforters.
E:\FR\FM\21FEN1.SGM
21FEN1
]]>Agencies
[Federal Register Volume 73, Number 35 (Thursday, February 21, 2008)]
[Notices]
[Pages 9592-9593]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-3175]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 2, 2008, Siemens
Healthcare Diagnostics Inc., 100 GBC Drive, Mail Stop 514, Newark,
Delaware 19702, made application by letter to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Ecgonine (9180)............................ II
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to produce the listed controlled substances in
bulk to be used in the manufacture of reagents and drug calibrator/
controls which are DEA exempt products.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances
[[Page 9593]]
may file comments or objections to the issuance of the proposed
registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administrator, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 21, 2008.
Dated: February 13, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-3175 Filed 2-20-08; 8:45 am]
BILLING CODE 4410-09-P
